Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2020

View Archived Issues

Enrollment completed and interim data presented from DRIIV-1b study of AsiDNA

Kira secures investments to advance development of novel complement-targeted therapies

Curasight initiates preclinical study of uTREAT therapy in brain cancer

First patient treated in phase I study of MaaT-033

Medshine Discovery divulges KLKB1 inhibitors

HitGen patents HDAC inhibitors

Enrollment completed in phase III study of Covishield in India

Epitas Biosciences presents IDH2 inhibitors

Betta Pharmaceuticals synthesizes new KRAS mutant inhibitors

Shanghai Public Utilities Institute patents antibodies for SARS-CoV-2 infection

Sharing without oversharing: Quick-ish cleanup can preserve privacy in functional genomics datasets

Safety, pharmacology and preliminary efficacy of VT-1021 in patients with advanced solid tumors

First patient dosed in phase II study of tomivosertib plus chemotherapy in breast cancer

FDA allows IND application for AV-001 in hospitalized patients with COVID-19

BVX-0320 vaccine candidate shows promising preclinical efficacy against SARS-CoV-2

[124I]-RmAb158-scFv8D3 detects soluble Abeta changes following treatment

Selva begins phase I study with SLV-213 to treat COVID-19

Navidea reports further phase IIb data on Tc99m tilmanocept imaging for rheumatoid arthritis

Verrica reports phase II topline data on VP-102 for external genital warts

Denali achieves biomarker proof of concept for transport vehicle technology with DNL-310

Medicago's adjuvanted COVID-19 vaccine candidate advances into phase II/III

Trinomab cleared to begin phase I study in Australia with anti-tetanus toxin monoclonal antibody

Orchard presents new HSC gene therapy research programs in dementia and Crohn's disease